Company Overview - Shanghai Ruining Biotechnology Co., Ltd. completed nearly 100 million RMB in Series C financing, led by Fudan Science and Technology and Qiming Venture Partners, with Haoyue Capital as the exclusive financial advisor. The funds will be used for clinical advancement and commercialization of core products [2] - The company was established in 2018 and is headquartered in Shanghai, focusing on medical hydrogel technology platforms for innovative medical devices in major clinical scenarios such as tumor treatment [5] Products and Technology - The main products include: - Respacio® absorbable isolation hydrogel for tumor radiotherapy protection, which has completed domestic clinical trials and is included in the National Medical Products Administration's special review procedure for innovative medical devices. It has received breakthrough medical device designation from the FDA and has submitted an application for CE certification in Europe [5] - Tumor embolization hydrogel for the treatment of hypervascular malignant tumors, which is also included in the special review procedure [7] - Uterine adhesion prevention hydrogel, currently in the clinical enrollment stage [7] - The medical hydrogel technology platform is applicable in areas such as tumor radiotherapy protection, tumor interventional embolization, uterine adhesion prevention, tissue filling, tissue regeneration, and drug delivery [8] Financing History - The financing history of the company includes: - Series C on February 28, 2025, raising approximately 100 million RMB, led by Qiming Venture Partners and Fudan Science and Technology [10] - Series B on January 24, 2024, also raising approximately 100 million RMB [10] - Series A on September 23, 2022, and earlier rounds including angel investments [10] Patent Information - The company has several patents, including: - A rapid-dissolving hydrogel reagent kit, authorized on August 22, 2023 [11] - A chitosan-polyethylene glycol-lithium diatomite composite hydrogel, published on August 8, 2024 [11] - A drug-loaded embolization microsphere, authorized on December 28, 2022 [11]

Group 1 - Shanghai Ruining Biotechnology Co., Ltd. has completed nearly 100 million RMB in Series C financing, led by Fudan Science and Technology and Qiming Venture Partners, which will accelerate the clinical and commercialization of its core products [1] - The company, established in 2018, is a key player in China's "14th Five-Year Plan" for medical equipment and biomaterials, and has developed a leading medical hydrogel technology platform for innovative medical device solutions in major clinical scenarios such as tumor treatment [1] - Ruining Biotechnology has created several first-in-China and Best-in-Class products, covering multiple segments including tumor radiotherapy protection and tumor interventional embolization, and is expanding into high-potential fields like tissue filling and drug delivery [1] Group 2 - The tumor radiotherapy "absorbable isolation hydrogel" has completed domestic clinical trials and is progressing internationally, having received breakthrough medical device designation from the FDA and submitted for CE certification in Europe [1] - The tumor embolization hydrogel has been recognized as a national innovation product and is expected to replace existing embolization solutions, enhancing the safety and effectiveness of interventional treatments for patients with liver cancer [2] - The company’s core team consists of top international talents with strong R&D backgrounds and industrial experience, aiming to deepen technology platform development and address unmet clinical needs through innovative products [2] Group 3 - The founder of Ruining Biotechnology expressed gratitude for the support from shareholders, emphasizing the commitment to continuous technological breakthroughs and long-term value growth [3] - Fudan Science and Technology congratulated the company on its financing success, highlighting the team's ability to create a sustainable product matrix and the complete capability from scientific breakthroughs to industrialization [3] - The managing director of Haoyue Capital expressed confidence in the company's potential to expand in the international market, recognizing the efficiency and effectiveness of the team led by the founder [3]